SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

<table>
<thead>
<tr>
<th>Pfizer Inc</th>
<th>Pfizer Ltd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pharmaceuticals Group</td>
<td>Ramsgate Road</td>
</tr>
<tr>
<td>235 East 42nd Street</td>
<td>Sandwich, Kent</td>
</tr>
<tr>
<td>New York, New York 10017</td>
<td>CT13 9NJ</td>
</tr>
<tr>
<td>1-212-573-2222</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>+00 44 (0)1304 616161</td>
</tr>
</tbody>
</table>

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Fesoterodine Fumarate Tablets

| Trade Name: | TOVIAZ |
| Synonyms: | Fesoterodine Sustained Release (SR) Tablets |
| Chemical Family: | Not determined |
| Intended Use: | Pharmaceutical product for the treatment of overactive bladder |

2. HAZARDS IDENTIFICATION

Appearance: Blue tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: May be harmful if swallowed. May cause eye irritation if tablets are crushed or broken. (based on components).

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver and the developing fetus.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include dry mouth constipation, upset stomach, dry eyes, urinary tract infection, abdominal pain, back pain, inflammation of the pharynx (pharyngitis), painful urination, and difficulty with urination.

EU Indication of danger: Not classified


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
2. HAZARDS IDENTIFICATION

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fesoterodine fumarate</td>
<td>286930-03-8</td>
<td>Not Listed</td>
<td>Xn;R22</td>
<td>1.2-2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Xi;R36</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.Cat.3;R63</td>
<td></td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Talc (non-asbestiform)</td>
<td>14807-96-6</td>
<td>238-977-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Glycerol dibehenate
Opadry blue
Lactose Monohydrate
Hydroxypropyl methylcellulose
Xylitol

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon and nitrogen

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not determined
6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Fesoterodine fumarate
Pfizer OEL TWA-8 Hr: 35µg/m³

Microcrystalline cellulose
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³

Latvia OEL - TWA 2 mg/m³
OSHA - Final PELS - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Spain OEL - TWA 10 mg/m³

Talc (non-asbestiform)
ACGIH Threshold Limit Value (TWA) 2 mg/m³
Australia TWA 2.5 mg/m³
Austria OEL - MAKs 2 mg/m³
Belgium OEL - TWA 2 mg/m³
Bulgaria OEL - TWA 1.0 fiber/cm³

6.0 mg/m³
3.0 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Analytical Method:** Not available

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Environmental Exposure Controls:** Refer to specific Member State legislation for requirements under Community environmental legislation.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

---

**Material Name:** Fesoterodine Fumarate Tablets

---

9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State:** Film-coated tablets

**Molecular Formula:** Mixture

**Color:** Light blue or Blue

**Molecular Weight:** Mixture

**Solubility:** Highly soluble: Water

---

10. STABILITY AND REACTIVITY

**Chemical Stability:** Stable under normal conditions of use.

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
10. STABILITY AND REACTIVITY
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Fesoterodine fumarate
Rat Oral LD50 ~ 681 mg/kg
Mouse Oral LD50 ~ 316 mg/kg
Rat Intravenous NOAEL 10 mg/kg
Mouse Intravenous NOAEL 10 mg/kg

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

Lactose Monohydrate
Rat Oral LD50 29700 mg/kg

Microcrystalline cellulose
Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Talc (non-asbestiform)
Rat Oral LD50 > 1600 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Fesoterodine fumarate
Skin Sensitization - M & K Guinea Pig Negative
Eye Irritation Rabbit Irritant
Skin Irritation Rabbit Negative

Microcrystalline cellulose
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Fesoterodine fumarate
6 Month(s) Mouse Oral 25 mg/kg/day NOAEL None identified
13 Week(s) Rat Oral 5 mg/kg/day NOEL Liver
13 Week(s) Dog Oral 2.5 mg/kg/day NOAEL Cardiovascular system, Blood
9 Month(s) Dog Oral 2.5 mg/kg/day NOAEL Cardiovascular system, Gallbladder

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fesoterodine fumarate
Fertility and Embryonic Development Mouse Oral mg/kg/day NOAEL Negative
**SAFETY DATA SHEET**

Material Name: Fesoterodine Fumarate Tablets

Revision date: 24-Sep-2013

---

### 11. TOXICOLOGICAL INFORMATION

<table>
<thead>
<tr>
<th>Toxicity Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Duration</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo / Fetal Development</td>
<td>Mouse</td>
<td>Oral</td>
<td>15 mg/kg/day</td>
<td>NOAEL</td>
<td>Not Teratogenic, Embryotoxicity</td>
<td></td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rabbit</td>
<td>Subcutaneous</td>
<td>4.5 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
<td></td>
</tr>
<tr>
<td>Prenatal &amp; Postnatal Development</td>
<td>Mouse</td>
<td>Oral</td>
<td>60 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
<td></td>
</tr>
</tbody>
</table>

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

- **Fesoterodine fumarate**
  - Bacterial Mutagenicity (Ames) *Salmonella, E. coli* Negative
  - Chromosome Aberration Human Lymphocytes Negative
  - *In Vivo* Micronucleus Mouse Negative

- **Lactose Monohydrate**
  - *In Vitro* Bacterial Mutagenicity (Ames) Negative

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

- **Fesoterodine fumarate**
  - 2 Year(s) Mouse Oral 60 mg/kg/day NOAEL Not carcinogenic
  - 2 Year(s) Rat Oral 60 mg/kg/day NOAEL Not carcinogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

**Talc (non-asbestiform)**

- **IARC:** Group 3 (Not Classifiable)

---

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided. The active ingredient in this formulation may be harmful to aquatic organisms. Long-term adverse effects to aquatic organisms are possible.

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

- **Fesoterodine fumarate**
  - *Pseudokirchneriella subcapitata* (Green Alga) OECD EC50 72 Hours 20 mg/L
  - Activated sludge OECD EC50 3 Hours > 1000 mg/L
  - *Daphnia Magna* (Water Flea) OECD NOEC 21 Days 3.2 mg/L
  - *Brachydanio rerio* (Zebra fish) OECD NOEC 35 Days 11.5 mg/L

**Aquatic Toxicity Comments:** A greater than (> ) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

---

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:
D2a very toxic materials
D2b toxic materials

Fesoterodine fumarate
California Proposition 65 Not Listed

Glycerol dibehenate
California Proposition 65 Not Listed

Microcrystalline cellulose
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 232-674-9

Opadry blue
California Proposition 65 Not Listed

Lactose Monohydrate
California Proposition 65 Not Listed
Australia (AICS): Present

Talc (non-asbestiform)
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>238-877-9</td>
</tr>
</tbody>
</table>

Hydroxypropyl methylcellulose

<table>
<thead>
<tr>
<th>Material</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>Standard for the Uniform Scheduling for Drugs and Poisons:</td>
<td>Schedule 4</td>
</tr>
</tbody>
</table>

Xylitol

<table>
<thead>
<tr>
<th>Material</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>201-788-0</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.
R36 - Irritating to eyes.
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 2 - Hazard Identification. Updated Section 15 - Regulatory Information. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 7 - Handling and Storage. Updated Section 4 - First Aid Measures.


Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet